Viewing data from:

WELLBUTRIN XL

NDA

BUPROPION HYDROCHLORIDE | N021515 | BAUSCH HEALTH US LLC

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

278 trials from ClinicalTrials.gov — 9 recruiting, 4 active, 221 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors NCT03996265	Phase 3	Active	University of Rochester NCORP Research Base	422	2019-06-27 → 2026-08-05
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder NCT06233799	Phase 3	Active	National Institute on Drug Abuse (NIDA)	360	2024-07-01 → 2027-04-30
Combination of Novel Therapies for CKD Comorbid Depression NCT04422652	Phase 2	Active	Stony Brook University	201	2020-09-24 → 2027-04-01
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy NCT05646862	Phase 3	Active	Hoffmann-La Roche	420	2023-06-07 → 2029-03-30
Biomarkers and Pharmacogenomics for Precision Depression Therapy NCT07738497	N/A	Not Yet Recruiting	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	220	2026-07-01 → 2029-01-19
Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness NCT07714200	N/A	Not Yet Recruiting	VA Office of Research and Development	120	2027-03-01 → 2030-09-01
Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder NCT02129751	Phase 4	Not Yet Recruiting	Bausch Health Americas, Inc.	246	2026-06 → 2029-12
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder NCT07596212	Phase 1/2	Not Yet Recruiting	University of Illinois at Chicago	100	2026-09 → 2031-09
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis NCT06609343	Phase 1/2	Not Yet Recruiting	The University of Texas Health Science Center at San Antonio	16	2026-08-24 → 2027-01-30
A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients NCT07398404	Phase 1/2	Not Yet Recruiting	Medical University of South Carolina	64	2026-09-01 → 2031-06-30

Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.

VA Federal Supply Schedule

Government-negotiated contract prices | 6 NDCs (3 FSS, 3 Big4)

Lowest Price

$233.79

Highest Price

$593.92

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00187-0730-30WELLBUTRIN XL 150MG TAB	$234.13	Big4	Bausch Health US, LLC	04/30/2026
00187-0730-30WELLBUTRIN XL 150MG TAB	$234.13	FSS	Bausch Health US, LLC	04/30/2026
00187-0730-90WELLBUTRIN XL 150MG TAB	$593.92	Big4	Bausch Health US, LLC	04/30/2026
00187-0730-90WELLBUTRIN XL 150MG TAB	$593.92	FSS	Bausch Health US, LLC	04/30/2026
00187-0731-30WELLBUTRIN XL 300MG TAB	$233.79	Big4	Bausch Health US, LLC	04/30/2026
00187-0731-30WELLBUTRIN XL 300MG TAB	$233.79	FSS	Bausch Health US, LLC	04/30/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Wellbutrin XL (2024)

Total Spending

$81.9M

Total Claims

18,653

Beneficiaries

3,395

Avg Cost/Unit

$74.76

Spending Trend

$67.0M(2019)→$74.0M(2020)→$75.8M(2021)→$76.9M(2022)→$77.5M(2023)→$81.9M(2024)

YoY Change:+4.8%

5yr CAGR:+7.8%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain25 active DMFs13 inactive

22 active API suppliers hold Drug Master Files for this ingredient.

ERREGIERRE SPABUPROPION HYDROCHLORIDE USP

DMF 110541994

CHEMI SPABUPROPION HYDROCHLORIDE

DMF 118341996

OLON SPABUPROPION HYDROCHLORIDE

DMF 139271998

HIKAL LTDBUPROPION HYDROCHLORIDE USP

DMF 164762003

OLON SPABUPROPION HYDROCHLORIDE

DMF 177842004

ALIVUS LIFE SCIENCES LTDBUPROPION HYDROCHLORIDE USP

DMF 181632005

ZHEJIANG APELOA JIAYUAN PHARMACEUTICAL CO LTDBUPROPION HYDROCHLORIDE USP

DMF 182002005

DIVIS LABORATORIES LTDBUPROPION HYDROCHLORIDE USP

DMF 183062005

APITORIA PHARMA PRIVATE LTDBUPROPION HYDROCHLORIDE USP

DMF 191532006

JUBILANT BIOSYS LTDBUPROPION HYDROCHLORIDE USP

DMF 198352006

SUN PHARMACEUTICAL INDUSTRIES LTDBUPROPION HYDROCHLORIDE USP

DMF 202102007

ZHEJIANG SUPOR PHARMACEUTICALS CO LTDBUPROPION HYDROCHLORIDE USP

DMF 212222007

ALEMBIC PHARMACEUTICALS LTDBUPROPION HYDROCHLORIDE USP

DMF 220642008

AARTI PHARMALABS LTDBUPROPION HYDROCHLORIDE

DMF 272042013

HETERO DRUGS LTDBUPROPION HYDROCHLORIDE (PROCESS-II)

DMF 282972014

HIKAL LTDBUPROPION HYDROCHLORIDE USP [PROCESS-2]

DMF 284212014

CADILA PHARMACEUTICALS LTDBUPROPION HYDROCHLORIDE USP

DMF 285742014

ZYDUS LIFESCIENCES LTDBUPROPION HYDROCHLORIDE USP (PROCESS-II)

DMF 322482017

ZHEJIANG SHAXING TECHNOLOGY CO LTDBUPROPION HYDROCHLORIDE

DMF 342852019

CHEMECA DRUGS PRIVATE LTDBUPROPION HYDROCHLORIDE USP

DMF 354182020

GRANULES INDIA LTDBUPROPION HYDROCHLORIDE USP

DMF 356942021

SUN PHARMACEUTICAL INDUSTRIES LTDBUPROPION HYDROCHLORIDE USP (PROCESS-II)

DMF 394142024

EMNAR PHARMA PRIVATE LTDBUPROPION HYDROCHLORIDE

DMF 400882024

IPCA LABORATORIES LTDBUPROPION HYDROCHLORIDE USP

DMF 401462024

ZHEJIANG SYNCOZYMES BIO-PHARMACEUTICAL CO LTDBUPROPION HYDROCHLORIDE

DMF 420522025

NORDIC SYNTHESIS ABInactiveBUPROPION HYDROCHLORIDE

DMF 111961994

CILAG AGInactiveBUPROPION HYDROCHLORIDE

DMF 120891996

SOLMAG SPAInactiveBUPROPION HYDROCHLORIDE

DMF 138511998

SEVEN STAR PHARMACEUTICAL CO LTDInactiveBUPROPION HYDROCHLORIDE USP

DMF 177892004

UNION QUIMICO FARMACEUTICA SA (UQUIFA SA)InactiveBUPROPION HYDROCHLORIDE USP

DMF 179252004

ZHEJIANG SUPOR PHARMACEUTICALS CO LTDInactiveBUPROPION HYDROCHLORIDE USP

DMF 181232005

PHARMACEUTICAL WORKS POLPHARMA SAInactiveBUPROPION HYDROCHLORIDE

DMF 181272005

CADILA HEALTHCARE LTDInactiveBUPROPION HYDROCHLORIDE

DMF 192972006

HANZHONG HANJIANG VENTUREPHARM PHARMACEUTICAL LTDInactiveBUPROPION HYDROCHLORIDE

DMF 194202006

ZHEJIANG XINHUA PHARMACEUTICAL CO LTDInactiveBUPROPION HYDROCHLORIDE

DMF 200852006

DERIVADOS QUIMICOS SAUInactiveBUPROPION HYDROCHLORIDE

DMF 237422010

HETERO DRUGS LTDInactiveBUPROPION HYDROCHLORIDE

DMF 267522012

LUPIN LTDInactiveBUPROPION HYDROCHLORIDE USP

DMF 335112019

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

25 letters from Drugs@FDA

Date	Submission	Document
Nov 6, 2025	SUPPL -49	View Letter (PDF)
May 7, 2024	SUPPL -46	View Letter (PDF)
Mar 9, 2022	SUPPL -44	View Letter (PDF)
Jul 12, 2021	SUPPL -43	View Letter (PDF)
Nov 8, 2019	SUPPL -40	View Letter (PDF)
May 9, 2017	SUPPL -36	View Letter (PDF)
Aug 30, 2016	SUPPL -34	View Letter (PDF)
Jan 7, 2015	SUPPL -30	View Letter (PDF)
Jan 7, 2015	SUPPL -29	View Letter (PDF)
Jul 15, 2014	SUPPL -32	View Letter (PDF)
Aug 3, 2012	SUPPL -28	View Letter (PDF)
Jul 28, 2011	SUPPL -27	View Letter (PDF)
Jul 28, 2011	SUPPL -26	View Letter (PDF)
May 27, 2010	SUPPL -22	View Letter (PDF)
Jul 8, 2009	SUPPL -23	View Letter (PDF)
Jul 8, 2009	SUPPL -24	View Letter (PDF)
Aug 7, 2007	SUPPL -20	View Letter (PDF)
Jul 13, 2006	SUPPL -14	View Letter (PDF)
Jun 14, 2006	SUPPL -10	View Letter (PDF)
Jun 14, 2006	SUPPL -18	View Letter (PDF)
Mar 3, 2006	SUPPL -12	View Letter (PDF)
Jan 13, 2005	SUPPL -9	View Letter (PDF)
Oct 29, 2004	SUPPL -2	View Letter (PDF)
Jun 1, 2004	SUPPL -7	View Letter (PDF)
Sep 9, 2003	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 150MG

RLDAB3

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Aug 28, 2003

No patent or exclusivity listings for this strength.

#002 — 300MG

RLDAB3

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Aug 28, 2003